aot2022v55i2

Acta Oncologica Turcica 2022; 55: 116-127
121
Table 2. Survival times (months) with Kaplan Meier method and comparisons of groups
with Log rank test
n Exitus Median (95.0% CI) 5-years survival p
rate (%)
Overall survival 83 64 25 (17.74 - 32.26) 29.1 ± 5.2 N/A
Extracapsular invasion
Absent 49 32 51 (20.89 - 81.11) 45.9 ± 7.5 <0.001
Present 34 32 13 (8.72 - 17.28) 5.9 ± 4.0
Perineural invasion
Absent 24 13 67 (36.98 - 97.02) 59.1 ± 10.6 <0.001
Present 59 51 14 (8.36 - 19.65) 17.5 ± 5.1
Lymphovascular invasion
Absent 30 16 81 (39.32 - 122.68) 56.6 ± 9.6 <0.001
Present 53 48 14 (10.95 - 17.05) 14.3 ± 4.9
Surgical margin
Negative 74 55 28 (18.97 - 37.03) 32.7 ± 5.7 <0.001
Positive 9 9 7 (0.00 - 15.77) 0.0 ± 0.0
T stage
T1 & T2 16 9 75 (37.01 - 112.99) 59.3 ± 12.9 0.002
T3 34 26 27 (19.97 - 34.03) 33.6 ± 8.4
T4 33 29 13 (7.37 - 18.63) 10.6 ± 5.6
N stage
N0 20 9 84 (69.26 - 98.74) 78.6 ± 9.5 <0.001
N1 15 10 41 (11.67 - 70.33) 36.0 ± 13.3
N2 21 18 15 (3.04 - 26.96) 11.4 ± 7.4
N3 27 27 13 (8.00 - 18.00) 3.7 ± 3.6
TNM stage
Stage 1 12 5 84 (62.79 - 105.21) 81.8 ± 11.6 <0.001
Stage 2 14 9 61 (20.39 - 101.61) 53.9 ± 14.1
Stage 3 & 4 57 50 14 (10.83 - 17.17) 12.4 ± 4.6
Leakage
Absent 70 51 28 (14.09 - 41.91) 34.7 ± 5.9 <0.001
Present 13 13 2 (0.00 - 4.35) 0.0 ± 0.0
Infection
Absent 62 44 34 (17.41 - 50.59) 35.9 ± 6.4 0.001
Present 21 20 11 (2.03 - 19.97) 9.5 ± 6.4
Recurrence
Absent 50 32 45 (0.00 - 101.85) 48.6 ± 7.2 0.010
Present 33 32 23 (17.37 - 28.63) 3.0 ± 3.0
Albumin
< 3.5 15 14 4 (0.00 - 9.05) 20.0 ± 10.3 0.007
≥ 3.5 68 50 27 (17.10 - 36.90) 30.9 ± 5.9
CI: Confidence interval. Same letters denote the lack of statistically significant difference between
groups.
www.actaoncologicaturcica.com
Copyright©Ankara Onkoloji Hastanesi